Sinaptica Therapeutics™ is a Cambridge based, clinical stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The company’s SinaptiStim™ System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and non-invasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on published sham-controlled clinical data on gold-standard endpoints, the company's neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimer’s patients in over two decades, and is protected by multiple pending patents.